Arin Ghasparian – Virometix AG

The efficacy of vaccination against pneumococcal diseases such as pneumonia, inflammation of the brain, or blood poisoning decreases rapidly. Reason: The vaccines consisting of isolated components of the bacterium cover only a small part of the approximately 90 pneumococcal subspecies. The biotech company Virometix uses a completely new technology, by means of which it wants to bring a purely synthetic vaccine to the market, which works against all subspecies and is still without side effect. In addition to the vaccine against pneumococcal bacteria, the company is also working on the development of a synthetic vaccine against viral infections.

Other team members

Arin Ghasparian